VA
KRYS icon

Vident Advisory’s Krystal Biotech KRYS Stock Holding History

Vident Advisory’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$417K Buy
1,614
+120
+8% +$31.9K ﹤0.01% 1350
2025
Q4 		$368K Buy
1,494
+76
+5% +$16K ﹤0.01% 1299
2025
Q3 		$250K Sell
1,418
-564
-28% -$84.4K ﹤0.01% 1479
2025
Q2 		$272K Sell
1,982
-805
-29% -$118K ﹤0.01% 1350
2025
Q1 		$502K Buy
2,787
+295
+12% +$49.6K 0.01% 1028
2024
Q4 		$390K Sell
2,492
-83
-3% -$14.7K 0.01% 1068
2024
Q3 		$469K Buy
2,575
+610
+31% +$118K 0.01% 954
2024
Q2 		$361K Buy
1,965
+549
+39% +$92.2K 0.01% 1052
2024
Q1 		$252K Buy
+1,416
New +$197K 0.01% 1113

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vident Advisory's KRYS Position: Q1 2026 in Review

Vident Advisory increased its Krystal Biotech (KRYS) stake by 8% in Q1 2026, buying an estimated $31.9K and bringing the position to 1,614 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Vident Advisory first reported a position in KRYS in Q1 2024 and has held it in 9 quarters since. The position peaked at $502K in Q1 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Vident Advisory held 1,614 shares of Krystal Biotech worth $417K as of Q1 2026.
  • Vident Advisory bought 120 Krystal Biotech shares in Q1 2026, an estimated $31.9K.
  • Krystal Biotech made up ﹤0.01% of Vident Advisory's portfolio in Q1 2026, its #1350 holding.
  • Vident Advisory first reported a position in Krystal Biotech in Q1 2024 and has held it in 9 quarters since.
  • Vident Advisory's Krystal Biotech position peaked at $502K in Q1 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.